EGFR+ Lung Cancer

In patients with EGFR-mutated non–small cell lung cancer, adjuvant treatment with osimertinib in the pivotal phase 3 ADAURA trial led to improvement in disease-free survival, irrespective of previous adjuvant chemotherapy received or disease stage.

Treatment with amivantamab induced deep and durable responses as well as promising survival as treatment of patients with previously treated non–small cell lung cancer harboring EGFR exon 20 insertion mutation in phase 1 CHRYSALIS trial.

Patients with EGFR-mutant, MET-amplified or -overexpressed non–small cell lung cancer and MET resistance treated with osimertinib in combination with savolitinib may be able to overcome resistance, according to final analysis findings.

During a Targeted Oncology Case-Based Peer Perspective Roundtable, Mary Jo J. Fidler, MD, discussed targeting VEGFR and EGFR in patients with non–small cell lung cancer.

Osimertinib has been a successful therapy for the treatment of EGFR-positive non–small cell lung cancer, surpassing the effects of chemotherapy. In he adjuvant setting, physicians questions when and how to use osimertinib.

Masahiro Tsuboi, MD, discusses the findings from the phase 3 ADAURA clinical trial of osimertinib as treatment of patients with EGFR-mutated non–small cell lung cancer.

The early unblinding of results from the phase 3 ADAURA clinical trial evaluating osimertinib, a third-generation EGFR tyrosine kinase inhibitor, was met with much fanfare in the oncology community as details of the interim results spread.

During a Targeted Oncology Case Based Peer Perspective event, John Heymach, MD, PhD Chair, Department of Thoracic/Head and Neck Medical Oncology The University of Texas MD Anderson Cancer Center, discusses the case of a 73-year-old Asian patients with EGFR-mutant non–small cell lung cancer.

The FDA has approved osimertinib as an adjuvant therapy for patients with non–small cell lung cancer whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test, for use following tumor resection.

During a Targeted Oncology Case Based Peer Perspectives event Karen L. Kelly, MD, discussed molecular testing guidelines and testing execution for early-stage non–small cell lung cancer as well as the research supporting the use of targeted therapies for treatment.

Edgardo S. Santos Castillero, MD, reviewed the case of a 73-year-old Asian man who was diagnosed with stage IV EGFR-mutant non-small cell lung cancer and discussed the treatment options he would consider for this patient.

The phase 3 LAURA clinical trial is currently enrolling patients with stage III, unresectable EGFR-mutant non–small cell lung cancer to explore the efficacy and safety of the third-generation tyrosine kinase inhibitor osimertinib as maintenance therapy following chemoradiation.

Masahiro Tsuboi, MD, discusses treatment with osimertinib for patients with EGFR-mutated non–small cell lung cancer and central nervous system disease recurrence.

A Biologics License Application was submitted to the FDA seeking approval of amivantamab as treatment of patients with metastatic non–small cell lung cancer harboring EGFR exon 20 insertion mutations whose disease progressed on/after platinum-based chemotherapy.

In an interview with Targeted Oncology, Pasi A. Jänne, MD, PhD, discussed the updated findings from the phase 1/2 study of mobocertinib as treatment of patients with non-small cell lung cancer who harbor an EGFR exon 20 insertions.

Target capture next-generation sequencing, MassARRAY, and real-time quantitative polymerase chain reaction all effectively detected low frequency somatic epidermal growth factor receptor mutations in cell-free circulating tumor DNA from individuals with non–small cell lung cancer , according to a presentation at the AMP 2020 Annual Meeting and Expo.

Alexander Spira, MD, PhD, discusses the phase 1 CHRYSALIS trial of amivantamab plus lazertinib in 2 EGFR-mutant non–small cell lung cancer patient populations, which include patients with relapsed/refractory and those who are treatment-naive.

In the treatment of EGFR-mutant non–small cell lung cancer, oncologists face multiple challenges with prescribing medications to patients. During a Targeted Oncology Case Based Peer Perspective event, Nathan Pennell, MD, PhD, discussed these challenges as well as potential treatment approaches with a group of peers.

Treatment with neratinib achieved a high percentage of responses in patients with metastatic non–small cell lung cancer patients with EGFR exon 18 mutations who were dosed in a cohort during the interim analysis of the phase 2 SUMMIT basket trial.

The FDA has granted approval to the cobas EGFR Mutation Test v2 as a companion diagnostic for EGFR tyrosine kinase inhibitors as treatment of patients with EGFR-mutant non–small cell lung cancer, which is the first assay approved for this indication.

In an interview with Targeted Oncology, Masahiro Tsuboi, MD, discussed the findings for the ADAURA study, which explored the role of osimertinib as treatment of patients with early-stage EGFR-mutant non-small cell lung cancer following a complete tumor resection.

In an interview with Targeted Oncology, Alexander Spira, MD, PhD, discussed the findings from the clinical trial evaluating amivantamab in combination with lazertinib as treatment of patients with advanced EGFR-mutant non-small cell lung cancer.

The FDA granted a Priority Review designation to adjuvant osimertinib as treatment of patients with stage IB/II/IIIA EGFR-mutant non–small cell lung cancer following a complete tumor resection with curative intent.

Masahiro Tsuboi, MD, discusses the key takeaways from the findings for osimertinib in patients with early-stage EGFR-mutant non–small cell lung cancer following a complete tumor resection in the phase 3 ADAURA clinical trial.

Atezolizumab in combination with bevacizumab, carboplatin, and paclitaxel demonstrated continued progression-free survival and overall survival benefit at 20 months of follow-up compared with chemotherapy alone in patients with chemotherapy-naïve metastatic nonsquamous non–small cell lung cancer who harbor an EGFR mutation, IMpower150 study results show.

In patients with early-stage EGFR mutated non–small cell lung cancer following complete tumor resection, treatment with osimertinib reduced the risk for central nervous system death or progression by 82%, findings presented during the EMSO Virtual Congress 2020.

Osimertinib plus bevacizumab did not lead to a prolonged progression-free survival compared with osimertinib alone as treatment of patients with advanced adenocarcinoma harboring EGFR T790M.

Findings from the phase 1 CHRYSALIS study showed that patients with advanced EGFR-mutant non–small cell lung cancer who were treatment naïve or resistant to osimertinib therapy had high response rates when treated with the combination of amivantamab and lazertinib. Results also demonstrated a favorable safety profile for the regimen, according to results reported at the ESMO Virtual Congress 2020.

The combination of apatinib and gefitinib demonstrated the feasibility of dual VEGFR/EGFR inhibition in patients with advanced EGFR-mutant non–small cell lung cancer, according to progression-free survival results of the phase 3 ACTIVE trial that were reported at the ESMO Virtual Congress 2020.

Patients with advanced lung adenocarcinoma who harbor EGFR T790M mutations did not experience significant progression-free survival improvement with osimertinib plus bevacizumab versus osimertinib alone, according to findings presented by Yukihiro Toi, MD, during the 2020 European Society for Medical Oncology Virtual Congress.